dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Motzer, Robert |
dc.contributor.author | Schmidinger, Manuela |
dc.contributor.author | Eto, Masatoshi |
dc.contributor.author | Suárez, Cristina |
dc.contributor.author | Figlin, Robert |
dc.contributor.author | Liu, Yanfang |
dc.date.accessioned | 2023-06-20T07:46:06Z |
dc.date.available | 2023-06-20T07:46:06Z |
dc.date.issued | 2023-01 |
dc.identifier.citation | Motzer RJ, Schmidinger M, Eto M, Suarez C, Figlin R, Liu Y, et al. LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy. Future Oncol. 2023 Jan;19(2):113–21. |
dc.identifier.issn | 1479-6694 |
dc.identifier.uri | https://hdl.handle.net/11351/9811 |
dc.description | Carcinoma de cèl·lules renals; Inhibidor del punt de control immunitari; Metastàtic |
dc.language.iso | eng |
dc.publisher | Future Medicine |
dc.relation.ispartofseries | Future Oncology;19(2) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Quimioteràpia combinada |
dc.subject | Ronyons - Càncer - Tractamemt |
dc.subject.mesh | Carcinoma, Renal Cell |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.title | LITESPARK-011: belzutifan plus lenvatinib vs cabozantinib in advanced renal cell carcinoma after anti-PD-1/PD-L1 therapy |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.2217/fon-2022-0802 |
dc.subject.decs | carcinoma de células renales |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.relation.publishversion | https://doi.org/10.2217/fon-2022-0802 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Motzer RJ] Memorial Sloan Kettering Cancer Center, New York, NY, USA. [Schmidinger M] Medical University of Vienna, Vienna, Austria. [Eto M] Kyushu University Hospital, Fukuoka, Japan. [Suarez C] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Figlin R] Cedars-Sinai Medical Center, Los Angeles, CA, USA. [Liu Y] Merck & Co., Inc., Rahway, NJ, USA |
dc.identifier.pmid | 36752726 |
dc.identifier.wos | 000931096400001 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |